Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pfizer (PFE – Research Report) and Fusion Pharmaceuticals (FUSN – Research Report).
Pfizer (PFE)
Truist Financial analyst Robyn Karnauskas maintained a Buy rating on Pfizer today. The company’s shares closed last Tuesday at $26.78, close to its 52-week low of $25.61.
According to TipRanks.com, Karnauskas is a 4-star analyst with an average return of
Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $31.71, which is a 18.5% upside from current levels. In a report issued on April 5, Cantor Fitzgerald also maintained a Buy rating on the stock with a $45.00 price target.
See today’s best-performing stocks on TipRanks >>
Fusion Pharmaceuticals (FUSN)
In a report released today, Nicole Germino from Truist Financial maintained a Hold rating on Fusion Pharmaceuticals. The company’s shares closed last Tuesday at $21.38, close to its 52-week high of $21.55.
Germino has an average return of
According to TipRanks.com, Germino is ranked #506 out of 8799 analysts.
Currently, the analyst consensus on Fusion Pharmaceuticals is a Hold with an average price target of $20.94.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PFE:
- Pfizer’s Abrysvo meets primary Phase 3 endpoint in RSV disease
- Notable open interest changes for April 8th
- ViiV Healthcare announces FDA approval of Dovato for adolescents with HIV
- CCI, PFE: 2 High-Yield Dividend Stocks to Buy, According to Analysts
- Sanofi to Resolve 4,000 Zantac Cancer Lawsuits in US Courts
